- Home
- ARTV vs ITOS Comparison
ARTV vs ITOS Comparison
Compare ARTV & ITOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARTV
- ITOS
- Stock Information
- Founded
- ARTV 2019
- ITOS 2011
- Country
- ARTV United States
- ITOS United States
- Employees
- ARTV N/A
- ITOS N/A
- Industry
- ARTV
- ITOS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ARTV
- ITOS Health Care
- Exchange
- ARTV NYSE
- ITOS Nasdaq
- Market Cap
- ARTV 39.0M
- ITOS 381.2M
- IPO Year
- ARTV 2024
- ITOS 2020
- Fundamental
- Price
- ARTV $1.61
- ITOS $10.18
- Analyst Decision
- ARTV Strong Buy
- ITOS Hold
- Analyst Count
- ARTV 8
- ITOS 6
- Target Price
- ARTV $18.14
- ITOS $10.60
- AVG Volume (30 Days)
- ARTV 302.9K
- ITOS 911.5K
- Earning Date
- ARTV 05-08-2025
- ITOS 08-07-2025
- Dividend Yield
- ARTV N/A
- ITOS N/A
- EPS Growth
- ARTV N/A
- ITOS N/A
- EPS
- ARTV N/A
- ITOS N/A
- Revenue
- ARTV N/A
- ITOS $35,000,000.00
- Revenue This Year
- ARTV N/A
- ITOS N/A
- Revenue Next Year
- ARTV N/A
- ITOS N/A
- P/E Ratio
- ARTV N/A
- ITOS N/A
- Revenue Growth
- ARTV N/A
- ITOS 177.89
- 52 Week Low
- ARTV $1.47
- ITOS $4.80
- 52 Week High
- ARTV $17.31
- ITOS $18.13
- Technical
- Relative Strength Index (RSI)
- ARTV N/A
- ITOS 67.13
- Support Level
- ARTV N/A
- ITOS $9.95
- Resistance Level
- ARTV N/A
- ITOS $10.19
- Average True Range (ATR)
- ARTV 0.00
- ITOS 0.15
- MACD
- ARTV 0.00
- ITOS -0.09
- Stochastic Oscillator
- ARTV 0.00
- ITOS 84.75
About ARTV ARTIVA BIOTHERAPEUTICS INC
Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205).
About ITOS iTeos Therapeutics Inc.
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.